RxDoctor Payments Data

Abdo Saba, MD

Psychiatry · East Stroudsburg, PANPI 1356418768

Payments from drug & device makers

$4,052in general payments, 2019–2025

Across 189 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$869
  • Otsuka America Pharmaceutical, Inc.$303
  • Sunovion Pharmaceuticals Inc.$161
  • Neurocrine Biosciences, Inc.$90
  • plus $73 from 2 others

What the payments were for

  • Food & beverage$3,94197%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,052 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,655
Medicare patients
39
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate45$151,109
Invega TrinzaPaliperidone Palmitate14$147,614
Abilify MaintenaAripiprazole23$67,731
Aripiprazole160$11,133
Haloperidol164$6,343
Chlorpromazine Hcl32$6,271
Paliperidone ErPaliperidone24$6,252
Olanzapine147$4,318
Trazodone Hcl379$3,819
Venlafaxine Hcl ErVenlafaxine Hcl307$2,710
Benztropine Mesylate230$2,657
Gabapentin184$2,594
Doxepin Hcl78$2,477
Hydroxyzine Hcl131$2,246
Haloperidol Decanoate46$2,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$1,288$298,72359 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$303$67,73123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in East Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →